Health Press Release – Newsletter for March 1, 2011

Shire Files Complete Response to FDA’s Not Approvable Letter for FIRAZYR(R) (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema

DUBLIN and LEXINGTON, Massachusetts, February 28, 2011 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today announced that it has submitted a complete
response to the not approvable letter issued by the US Food and Drug
Administration (FDA) to Jerini AG in April 2008 regarding its New Drug
Application for FIRAZYR(R) (icatibant) for the …. Read the original article  : here.

Global Consensus Demands Better Diabetic Foot Health Management

Basic Foot Care for Low-risk Patients is Critical to Reduce Complications
LONDON, February 28, 2011 – A global consensus published this month in Diabetic Medicine aims to help
people with diabetes who are presently at low-risk of foot complications to
undertake a basic foot care regimen in order to reduce their likelihood of
developing serious foot complications in …. Original article on Gaea Times at  : Global Consensus Demands Better Diabetic Foot Health Management.

Santaris Pharma A/S Obtains Exclusive License from Mass General Hospital for Intellectual Property Related to the Regulation of miR-33 for the Treatment of Cardiovascular Disorders

miR-33, an important microRNA that regulates high density lipoprotein (HDL) levels or "good" cholesterol, is a promising therapeutic target for raising good cholesterol levels

HOERSHOLM, Denmark and SAN DIEGO, February 28, 2011 – Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused
on the research and development of mRNA and microRNA targeted therapies,
today announced that …. Source  : Santaris Pharma A/S Obtains Exclusive License from Mass General Hospital for Intellectual Property Related to the Regulation of miR-33 for the Treatment of Cardiovascular Disorders.

Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation

SUNNYVALE, California, February 28, 2011 – Intuity Medical, Inc.(TM), a privately-held company developing innovative
technologies in diabetes management, announced that it has secured a $20M
credit facility from Silicon Valley Bank and Oxford Finance Corporation. The
funds will be used to help complete clinical trials and commercialize
POGO(TM), a fully-integrated blood glucose monitoring system.

Intuity … Original source on Gaea Times at : Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation.

Peripheral Neuropathic Pain Patients in Sweden set to Benefit From First-of-a-Kind Treatment Which Provides Lasting Pain Relief

Decision to Reimburse Qutenza(TM) (capsaicin 8% w/w dermal patch) by Sweden's Dental and Pharmaceutical Benefits Agency (Tand-och Lakemedelsformansverket) Gives new Option to Patients Living With Difficult-to-Treat Condition

STAINES, England, February 28, 2011 – Patients in Sweden living with peripheral neuropathic pain are set to
gain access to a new treatment option which can provide pain relief … Original article on : Peripheral Neuropathic Pain Patients in Sweden set to Benefit From First-of-a-Kind Treatment Which Provides Lasting Pain Relief.

Shire Lends Support to World Rare Disease Day 2011

CAMBRIDGE, Massachusetts and BASINGSTOKE, England, February 28, 2011 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today announced its support of World Rare Disease
Day, joining patients, physicians, and patient organizations around the world
to support a day that focuses attention on rare diseases as a public health
issue and highlights the need for …. Source article on Gaea Times at  : Shire Lends Support to World Rare Disease Day 2011.

Renishaw Diagnostics Enables Customised Multiplex Assays for Precious Research Samples

GLASGOW, Scotland, February 28, 2011 – Renishaw Diagnostics Ltd, a world leading provider of trace
level detection technologies based on the exploitation of surface enhanced
Raman scattering (SERS) and surface enhanced resonance Raman scattering
(SERRS), for research and molecular diagnostics applications, today announced
the launch of its first research use only (RUO) multiplex assay system which
allows precious research …. Source  : Renishaw Diagnostics Enables Customised Multiplex Assays for Precious Research Samples.

Barbados Is Proud of Leading Medical Facility

LONDON, February 28, 2011 – Barbados Fertility Centre is celebrating this week after receiving the
gold seal of approval from Joint Commission International (JCI), who have
reaccredited Barbados Fertility Centre (BFC), meaning the clinic has
maintained the highest standards since the gold seal was first awarded to
them in 2007.

Ann Jacobson, Executive Director at …. Read the original article  : here.

Health Robotics Announces Termination of its Distribution Contract With McKesson Corporation in North America

BOZEN, Sud-Tirol, Italy, February 28, 2011 – Health Robotics today announced that earlier last week, it served proper
notice to McKesson of the immediate termination for cause of their exclusive
CytoCare distribution and services contract in North America, as well as the
termination for cause of their non-exclusive distribution agreement for
i.v.STATION and i.v.SOFT within a subset of …. Original article on Gaea Times at  : Health Robotics Announces Termination of its Distribution Contract With McKesson Corporation in North America.

Chiltern – Spectratox Drug Photoxicity Collaboration Celebrates 25 Years

LONDON, February 28, 2011 – The staffs of Chiltern International Limited (Chiltern), a global
contract research organization (CRO), and Spectratox Limited, celebrate the
25 year mark of their successful collaboration in Drug Phototoxicity.

Chiltern Early Phase and Spectratox have worked together using a
validated and regulatory accepted in vivo human study method for the
assessment … Read the original article on Gaea Times at : Chiltern – Spectratox Drug Photoxicity Collaboration Celebrates 25 Years.

Infinity Group Invests 120 Million RMB in Shijiazhuang Xingbai Pharmaceutical Company Limited, China

SHIJIAZHUANG, China, February 28, 2011 – Infinity Group, an RMB fund pioneer and the leader in cross border China
RMB and dollar private equity funds, announced today that it is investing 120
million RMB ($US18 million) in Shijiazhuang Xingbai Pharmaceutical Company
Limited. Four of Infinity's funds – the SJZ fund, the I-China fund, the
Changzhou fund and the … Original article on : Infinity Group Invests 120 Million RMB in Shijiazhuang Xingbai Pharmaceutical Company Limited, China.

Toxic Sleep: The Silent Epidemic

SKIPTON, England, March 1, 2011 – Grotty old beds could be behind a growing epidemic of 'toxic sleep'.

A new Sleep Council survey* for National Bed Month (March) shows nearly
half of us are getting just six hours sleep or less a night. And an alarming
four out of five people complain of … Read more : Toxic Sleep: The Silent Epidemic.